Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
BACHEM: 10-year investment would have returned a 402.74% gain
Ten years ago the BACHEM share closed at CHF 14.97; with the closing price of CHF 75.25 on 14 August 2026, an investment of CHF 10,000 would be worth CHF 50,274.35 today, equivalent to a gain of 402.74 percent. BACHEM's market capitalization was most recently CHF 5.63 billion. The calculation does not take stock splits and dividends into account. » Altro su finanzen.net
BACHEM surpasses analysts' expectations in H1 2026 thanks to expansion of production capacities
BACHEM reports revenue of CHF 326.4m for the first half of 2026 (+4.3% or +7.3% in local currency) and a net profit of CHF 50.3m, beating estimates. EBITDA fell 9% to CHF 82.8m and the margin declined to 25.4%; charges arose from start‑up costs of the new "Gebäude K" plant in Bubendorf. BACHEM invested CHF 148.4m in H1 and confirms full‑year investments of CHF 350–400m as well as a revenue growth target of 35–40% for 2026. At full capacity of the new plants, a markedly better second half and an EBITDA margin in the low thirties in local currency are expected. Boris Corpataux will become chief commercial officer and a member of the corporate executive committee effective 1 August 2026. » Altro su finanzen.net
BACHEM: one-year return of 0.81% on a CHF 10,000 investment
Someone who had invested CHF 10,000 in BACHEM stock a year ago would have CHF 10,080.59 today, representing an increase of 0.81%. The closing price is CHF 75.05 and the market capitalization is around CHF 5.62 billion. Stock splits and dividends are not included in the calculation. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 353,66 Mio | - |
| Utile lordo | 88,46 Mio | - |
| Utile netto | 54,46 Mio | - |
| EBITDA | 89,12 Mio | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 6,09 Mrd€ |
Numero di azioni | 74,94 Mio |
Massimo/minimo a 52 settimane | 88,85€ - 51,78€ |
| Dividendi | No |
Beta | 0,8 |
Rapporto P/E | 38,24 |
Rapporto PEG | 3,42 |
Rapporto P/B | 3,95 |
Rapporto P/S | 8,05 |
Profilo aziendale
Die Bachem Holding AG liefert Produkte für die Forschung, die klinische Entwicklung und die kommerzielle Anwendung an Pharma- und Biotechnologieunternehmen weltweit. Das Unternehmen befasst sich mit der Entwicklung, Produktion und regulatorischen Unterstützung von peptidischen pharmazeutischen Wirkstoffen, wie Peptid- und Oligonukleotid-NCEs (New Chemical Entities). Darüber hinaus bietet es kommerzielle NCEs und Generika sowie Dienstleistungen in den Bereichen Projektmanagement, Qualität und Regulierung, Analytik, Produktion nach guter Herstellungspraxis, Produktion in Forschungsqualität sowie Lieferung und vertikale Integration an. Das Unternehmen wurde 1971 gegründet und hat seinen Hauptsitz in Bubendorf, Schweiz. Die Bachem Holding AG ist eine Tochtergesellschaft der Ingro Finanz AG.
| Nome | Bachem Holding |
| CEO | Anne-Kathrin Stoller |
| Sede centrale | Bubendorf,
bl Svizzera |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 17/07/1998 |
| Dipendenti | 2.725 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
SIX | BANB.SW |
Scopri gli asset
Gli azionisti di Bachem Holding investono anche nei seguenti asset
